Serum metabolic signatures of coronary and carotid atherosclerosis and subsequent cardiovascular disease by Tzoulaki, I. et al.
Serummetabolic signatures of coronary and
carotid atherosclerosis and subsequent
cardiovascular disease
Ioanna Tzoulaki 1,2,3,4*,†, Raphae¨le Castagne´1,5†, Claire L. Boulange´6,7†,
Ibrahim Karaman 1,2,4, Elena Chekmeneva7, Evangelos Evangelou1,2,3,
Timothy M.D. Ebbels7, Manuja R. Kaluarachchi6,7, Marc Chadeau-Hyam1,2,
David Mosen1,2, Abbas Dehghan1,2,4, Alireza Moayyeri8, Diana L. Santos Ferreira9,
Xiuqing Guo10,11, Jerome I. Rotter10,11, Kent D. Taylor10,11, Maryam Kavousi12,
Paul S. de Vries12,13, Benjamin Lehne1, Marie Loh1, Albert Hofman12,14,
Jeremy K. Nicholson6,7, John Chambers1,15, Christian Gieger16, Elaine Holmes6,7,
Russell Tracy17, Jaspal Kooner14,18, Philip Greenland19, Oscar H. Franco11,20,
David Herrington21†, John C. Lindon6,7†, and Paul Elliott 1,2,4*,†
1Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, London W2 1PG, UK; 2MRC-PHE Centre for Environment and
Health, School of Public Health, Imperial College London, Norfolk Place, London W2 1PG, UK; 3Department of Hygiene and Epidemiology, University of Ioannina Medical
School, University Campus Road 455 00, Ioannina, Greece; 4Dementia Research Institute, Imperial College London, Norfolk Place, London W2 1PG, UK; 5LEASP, UMR 1027,
Inserm-Universite´ Toulousse III Paul Sabatier, Toulousse 31000, France; 6Metabometrix Ltd, Imperial Incubator, Bessemer Building, Prince Consort Road, London SW7 2BP, UK;
7Division of Computational and Systems Medicine, Department of Surgery and Cancer, Imperial College London, South Kensington Campus, London SW7 2AZ, UK; 8Farr
Institute of Health Informatics Research, University College London Institute of Health Informatics, 222 Euston Road, London NW1 2DA, UK; 9MRC Integrative Epidemiology
Unit, School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfiled Grove, Bristol BS8 2BN, UK; 10Department of Pediatrics, Institute for
Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1000 W Carson St, Torrance, CA 90502, USA;
11Department of Medicine, Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1000 W
Carson St, Torrance, CA 90502, USA; 12Department of Epidemiology, Erasmus University Medical Center, University Medical Center Rotterdam, PO Box, 2040, 3000 CA
Rotterdam, the Netherlands; 13Department of Epidemiology, Human Genetics, and Environmental Sciences, Human Genetics Center, School of Public Health, The University of
Texas Health Science Center at Houston, 1200 Pressler Street, Houston, TX 77030, USA; 14Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677
Huntington Avenue, Boston, MA 02115, USA; 15London North West Healthcare NHS Trust, Northwick Park Hospital, Watford Rd, Harrow, HA1 3UJ, UK; 16German Research
Centre for Environmental Health, Helmholtz Zentrum Mu¨nchen, Ingolsta¨dter Landstraße 1, D-85764 Neuherberg, Germany; 17M.D. College of Medicine University of Vermont,
The Robert Larner, Given Medical Bldg, E-126, 89 Beaumont Ave, Burlington, VT 05405, USA; 18National Heart & Lung Institute, Faculty of Medicine, Imperial College London,
Guy Scadding Building, Dovehouse St, Chelsea, London SW3 6LY, UK; 19Department of Preventive Medicine, Northwestern University, Feinberg School of Medicine, 680 North
Lake Shore Drive, Suite, 1400, Chicago, IL 60611, USA; 20Institute of Social and Preventive Medicine (ISPM), University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland; and
21Section on Cardiovascular Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem,
NC 27157, USA
Received 22 August 2018; revised 21 November 2018; editorial decision 12 February 2019; accepted 13 May 2019; online publish-ahead-of-print 18 May 2019
See page 2897 for the editorial comment on this article (doi: 10.1093/eurheartj/ehz252)
Aims To characterize serum metabolic signatures associated with atherosclerosis in the coronary or carotid arteries and
subsequently their association with incident cardiovascular disease (CVD).
...................................................................................................................................................................................................
Methods
and results
We used untargeted one-dimensional (1D) serum metabolic profiling by proton nuclear magnetic resonance spec-
troscopy (1H NMR) among 3867 participants from the Multi-Ethnic Study of Atherosclerosis (MESA), with replica-
tion among 3569 participants from the Rotterdam and LOLIPOP studies. Atherosclerosis was assessed by coronary
artery calcium (CAC) and carotid intima-media thickness (IMT). We used multivariable linear regression to evaluate
associations between NMR features and atherosclerosis accounting for multiplicity of comparisons. We then exam-
ined associations between metabolites associated with atherosclerosis and incident CVD available in MESA and
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Rotterdam and explored molecular networks through bioinformatics analyses. Overall, 30 1H NMR measured metab-
olites were associated with CAC and/or IMT, P= 1.3  10-14 to 1.0  10-6 (discovery) and P= 5.6  10-10 to 1.1  10-2
(replication). These associations were substantially attenuated after adjustment for conventional cardiovascular risk fac-
tors. Metabolites associated with atherosclerosis revealed disturbances in lipid and carbohydrate metabolism, branched
chain, and aromatic amino acid metabolism, as well as oxidative stress and inflammatory pathways. Analyses of incident
CVD events showed inverse associations with creatine, creatinine, and phenylalanine, and direct associations with man-
nose, acetaminophen-glucuronide, and lactate as well as apolipoprotein B (P< 0.05).
...................................................................................................................................................................................................
Conclusion Metabolites associated with atherosclerosis were largely consistent between the two vascular beds (coronary and
carotid arteries) and predominantly tag pathways that overlap with the known cardiovascular risk factors. We pre-
sent an integrated systems network that highlights a series of inter-connected pathways underlying atherosclerosis.
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Introduction
Atherosclerosis and its clinical complications, mainly cardiovascular
disease (CVD), is a leading cause of death and disability worldwide.1,2
Epidemiological and laboratory research have provided insight into
the molecular mechanisms associated with the pathophysiology of
atherosclerosis.3–5 Conventional cardiovascular risk factors (such as
smoking, hypertension, and dyslipidaemia) are well-established.
However, it is not well understood how these risk factors mechanis-
tically cause atherosclerosis and whether independent pathways exist
that bypass these conventional factors altogether.6 Such further
understanding of the molecular pathways underlying atherosclerotic
disease may facilitate novel strategies which interrupt, reverse, or pre-
vent its initiation prior to clinical disease. Untargeted metabolic phe-
notyping (metabolomics), through the simultaneous measurement of
a wide range of low molecular weight molecules in biological samples,
offers the opportunity to provide a high-resolution picture of biologic-
al signatures underlying complex traits as well as potential for new
prognostic and diagnostic markers.7 In this study, we examined the
serum metabolic signature of measures of subclinical atherosclerosis
in carotid and coronary arteries using untargeted metabolic profiling
by high-resolution proton nuclear magnetic resonance (1H NMR)
spectroscopy in the Multi-Ethnic Study of Atherosclerosis (MESA) co-
hort, with replication in independent data from the Rotterdam and
the London Life Sciences Prospective Population Study (LOLIPOP)
studies. We also performed some additional analyses. First, we exam-
ined whether replicated metabolites were independent of main car-
diovascular risk factors. We also tested these metabolites against
incident CVD events regardless of their independence with cardiovas-
cular risk factors. Finally, we performed gene and molecular network
mapping to investigate the molecular pathways underlying their associ-
ation with subclinical and clinically manifest atherosclerosis.
Methods
Study samples
Metabolic profiling was performed on stored serum samples randomly
selected from the baseline clinic exams of three population-based
cohorts: MESA (N= 3867), LOLIPOP (N= 1917), and Rotterdam Study
(N= 1652). In brief, MESA is a prospective cohort of 6814 US participants
aged 45 to 84 years recruited via six field centres between 2000 and
2002.8 Participants were free of known CVD at baseline and were
recruited from four ethnicities (White, African-American, Chinese-
American, and Hispanic). The Rotterdam Study is a prospective cohort
study in the Ommoord district of the city of Rotterdam, the Netherlands.
At baseline, between 1990 and 1993, 7983 participants over 55 years old
were interviewed at home and underwent extensive clinical examination
at the research centre.9 The third visit took place between 1997 and
1999, and included 4797 participants. LOLIPOP is a prospective cohort
study of 28 372 people from 35 to 74 years old living in West London,
UK from two main ethnic groups (European and South Asian) recruited
between 2002 and 2008.10
Subclinical atherosclerosis was assessed by coronary artery calcium
(CAC) measured by computerized tomography, quantified using the
Agatston score, and intima-media thickness (IMT)11–13 measured by ca-
rotid ultrasound at baseline clinic exams in all three cohorts. In each co-
hort, we used the mean of the maximum far wall IMT from scans of the
right and left common carotid arteries using comparable protocols.
Standard cardiovascular risk factors and biomarkers, along with data on
treatment and lifestyle characteristics were obtained in all three cohorts
as previously described.5–7 Cardiovascular disease events [myocardial in-
farction (MI) and stroke] were available in MESA [after median 10 years
of follow-up] and the Rotterdam Study [after median 11 years of follow-
up].8,14,15 Study design is summarized in Supplementary material online,
Figure S1.
Proton nuclear magnetic resonance
metabolic profiling
Nuclear magnetic resonance measurements were carried out using a pre-
viously published protocol16 (see Supplementary material online, for
expanded Methods section). A standard 1H NMR one-dimensional (1D
NMR) spectrum with water suppression (also called the NOESY-presat
sequence) and a T2-edited spectrum using the Carr-Purcell-Meiboom-
Gill (CPMG) sequence were obtained for each sample. The standard 1H
NMR spectrum detects signatures of all proton containing compounds,
with the resultant spectrum comprising sharp peaks for small molecule
species, broad bands from the lipoproteins and a largely featureless back-
ground from proteins. The CPMG experiment exploits the variation in
the nuclear spin relaxation times of the large and small molecules to re-
duce the intensities of the broad signals from the large compounds
2884 I. Tzoulaki et al.
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(proteins and lipoproteins) producing a spectrum with a flatter baseline
and mainly small molecule metabolite peaks. The acquisition parameters
of each experiment are detailed in the Supplementary material online.
The spectral processing was performed using the software TOPSPIN 3.1
(Bruker Biospin, Rheinstetten, Germany). For each spectrum, the free in-
duction decay underwent a zero filling by a factor of two and a line broad-
ening of 0.3 Hz producing 128K frequency domain points prior to Fourier
transformation. The spectra were then automatically phased and baseline
corrected, and the chemical shifts were calibrated to the glucose signal at
5.233 ppm. Spectral data were imported into MATLAB [Version 8.3
(R2014a) Mathworks Inc., Natwick, MA, USA] for further processing.
The 1H NMR spectroscopic analysis was completed in six batches corre-
sponding to the three cohorts and two 1H NMR measurement (experi-
mental) phases. The processing workflow to integrate the multicohort
1H NMR metabolic profiling data has previously been described17 and
further details are in Supplementary material online, Data Supplement.
Proton nuclear magnetic resonance
lipoprotein profiles
We quantified lipoprotein subclasses from the MESA 1H NMR data based
on the deconvolution of the methyl (at 0.84–0.93 ppm) and methylene
resonances (at 1.22–1.26 ppm) using a proprietary procedure (developed
by Bruker Biospin, Rheinstetten, Germany) adapted from Petersen
et al.18 To assess measurement quality, the Pearson correlation coeffi-
cients between conventional measurements and the Bruker 1H NMR-
derived values for total high-density lipoprotein (HDL) and low-density
lipoprotein (LDL) and triglycerides were calculated. Analysis of 105 lipo-
protein subclasses was carried out including different chemical compo-
nents of intermediate-density lipoprotein (density 1.006–1.019 kg/L),
very low-density lipoproteins (VLDL, 0.950–1.006 kg/L), LDL (density
1.09–1.63 kg/L), and HDL (density 1.063–1.210 kg/L). The LDL sub-
fraction was fractionated into six density classes (LDL-1 1.019–1.031 kg/
L, LDL-2 1.031–1.034 kg/L, LDL-3 1.034–1.037 kg/L, LDL-4 1.037–
1.040 kg/L, LDL-5 1.040–1.044 kg/L, and LDL-6 1.044–1.063 kg/L) and the
HDL sub-fraction in four density classes (HDL-1 1.063–1.100 kg/L, HDL-
2 1.100–1.125 kg/L, HDL-3 1.125–1.175 kg/L, and HDL-4 1.175–1.210 kg/
L).18,19
Metabolite identification
To help with identification of peaks in the 1H NMR data, reduction using
a semi-automatic clustering of the full resolution 1H NMR spectrum
(30 590 features) was performed using the statistical recoupling of varia-
bles (SRV).20 The algorithm identifies clusters of 10 or more consecutive
resonance features with a correlation of r >_0.9; clusters could also be
grouped into a supercluster if the correlation with the neighbouring clus-
ter was r= 0.9 or above. To optimize the efficiency of SRV, superclusters
were generated from the aggregation of a maximum of three clusters
according to Blaise et al.21 Each cluster was then manually checked (blind
to knowledge of atherosclerosis status) to improve the groupings and
identify peak overlaps. Thus, 132 clusters were identified in 1H NMR
standard 1D and 157 clusters in CPMG data, each of them corresponding
to a single peak or a group of peaks.
The chemical shift (in ppm), the coupling constant value (J in Hz), the
peak multiplicity (singlet, doublet, and multiplet), and peak connectivity of
the NMR signals of interest were identified using 1D and 2D [2D JRES,
COrrelation SpectroscopY (COSY), TOtal Correlation SpectroscopY
(TOCSY), Heteronuclear single quantum correlation spectroscopy
(HSQC)] NMR experiments and statistical correlation methods
[STOCSY (Statistical Total Correlation Spectroscopy) and STORM
(Subset Optimisation by Reference Matching)].22,23 This information was
then compared with available in-house and publicly available databases
(Human Metabolome Database24) as well as with published data on
human serum and plasma metabolite components. The metabolite identi-
ties were confirmed by spike-in experiments when the chemical stand-
ards were available (Supplementary material online, Figures S2–S5). The
level of peak overlap in the clusters of interest and the level of confidence
in the assignment of the identified metabolites were adapted from
Sumner et al.25 The metabolite assignment is as follows: (i) compound
identified with spiking, (ii) annotated compounds (without chemical refer-
ence standards, based upon physicochemical properties, and/or spectral
similarity with public/commercial spectral libraries), (iii) putatively charac-
terized compound classes (e.g. based upon characteristic physicochemi-
cal properties of a chemical class of compounds, or by spectral similarity
to known compounds of a chemical class), and (iv) unknown compounds
(a) well-resolved peaks which can be differentiated and quantified based
upon spectral data; (b) overlapped or poorly resolved peaks, from which
signal differentiation and quantification may be compromised.
Statistical analysis
Main analysis
CAC (Agatston score) was transformed to ln(CACþ 1) and IMT to
log10(IMT) for all analyses. We first carried out analyses in the MESA
study data and then took forward significantly associated features for rep-
lication in the Rotterdam Study and LOLIPOP data. In MESA, for each of
the 30 590 spectral features, we carried out a linear regression against
each of CAC and IMT with adjustment for age, gender, ethnicity, and
measurement phase (Model 1). Discovery models used partial Spearman
correlations between CAC or IMT and metabolic features along with P
values to indicate the strength of associations. We also presented results
as standardized regression coefficients (per standard deviation) from lin-
ear regression. Each of the 30 590 spectral features were standardized
(mean-centred and scaled to unit variance) when standardized beta coef-
ficients were presented. To take into account the high degree of correl-
ation in spectral data, we used a permutation-based method to estimate
across the three cohort studies the Metabolome Wide Significance Level
(MWSL or a’).26,27 For each permutation, we randomly allocate the out-
come of interest to each study participant across cohort studies to mimic
the null hypothesis of no association; we then calculate the P-value for
each spectral variable using a linear regression model as described above
and record the lowest P-value. We ran 10 000 permutations per out-
come (CAC or IMT) for both 1D NMR and CPMG spectra. The per-
variable significance level a’ giving a 5% Family-Wise Error Rate (FWER,
a) corresponds to the 500th of these lowest P-values. The effective num-
ber of tests (ENT) is defined as the number of independent tests that
would be required to obtain the same significance level using Bonferroni
correction: ENT = a/a’. We computed P-value thresholds for each com-
bination of model, outcome, and 1H NMR assay type, as summarized in
Supplementary material online, Table S1 and defined a unified threshold
derived from the median ENT for both 1D NMR and CPMG as there was
little variation between the ENT of the different analyses. The ENT impli-
citly quantifies the level of dependency within the data. Features (individ-
ual ppms) that were significantly (MWSL) associated with either CAC or
IMT in MESA were annotated (as described in the metabolite identifica-
tion section, above) and within each cluster we selected the ‘sentinel’ fea-
ture with the lowest P-value. In tables, we present the cluster with the
lowest P-value per metabolite, as more than one cluster may correspond
to the same metabolite. We then took these features forward for replica-
tion in the Rotterdam Study and LOLIPOP using regression models with
adjustment for the same confounders, and further adjusting for cohort.
Features with P <0.05 for the same outcome of interest and with a con-
sistent direction of association as in MESA were considered replicated.
We considered replicated metabolites our principal finding (as reported
Metabolic signatures of atherosclerosis 2885
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in our main Figures and Abstract) and also performed additional investiga-
tions, as detailed below.
Additional analyses
We examined in the three cohorts combined the association between
replicated features and atherosclerosis (separately for CAC and IMT)
adjusting also for the main cardiovascular risk factors [LDL and HDL chol-
esterol, systolic blood pressure, smoking status (current, past, and never
smoker), and diabetes) as well as lipid and blood pressure lowering treat-
ment (Model 2). We also examined associations between replicated fea-
tures and incident cardiovascular events (MI and Stroke) in MESA and the
Rotterdam Study using Cox regression with adjustment for the same set
of confounders as in Model 2 above and with duration of follow-up as the
time metric. Proportional hazards assumptions were tested using
Schoenfeld residuals implemented in R Package Survival and risk esti-
mates were presented as hazard ratio (incident event data were unavail-
able in the LOLIPOP study). For metabolites that were significant at
MWSL level in Model 2, we performed stepwise linear regression for
CAC and IMT separately in MESA with all Model 2 confounders forced in
the model as implemented in the R package ‘bootStepAIC’28 on 1000
bootstrap samples. Results are summarized by counting how many times
each variable is selected and how many times the estimate of the regres-
sion coefficient of each variable changed signs. We performed analyses
on the Bruker lipoprotein data for MESA samples, using linear regression
models with adjustment for Model 2 confounders except for blood lipids
(LDL and HDL cholesterol) (Model 3: age, sex, ethnicity, phase, systolic
blood pressure, smoking status, and diabetes, lipid and blood pressure
lowering treatment). Principal component analysis of the 105 lipoproteins
concentration showed that 10 principal components explained more
than 95% of the total variation in the data set. Therefore, the Bonferroni
corrected significance level accounting for the correlation in the data was
P= 0.05/10 (P= 0.005) in these analyses.
Finally, in MESA, we examined associations between replicated meta-
bolic features and cardiometabolic risk factors [body mass index (BMI),
waist circumference, systolic blood pressure, diabetes, LDL and HDL
cholesterol, and inflammatory biomarkers] using linear regression
adjusted for model two confounders. Results are presented via a correl-
ation matrix.
We performed sensitivity analyses excluding individuals with diabetes
treatment (N= 765) or blood pressure treatment (N= 2603) or lipid
lowering treatment (N= 1196) and finally excluding individuals with self-
reported diabetes or on diabetes treatment (N= 1060). We also exam-
ined models with adjustment for BMI in addition to cardiovascular risk
factors included in Model 2.
All analyses were performed using the R project software
(‘Development Core Team, R’, 2005) using packages rockchalk to esti-
mate the partial correlation29 and openxlsx to write results file30 as well
as multiple helper functions to manipulate and visualize data.31–34
Metabolic reaction network
The Metabonetwork method35 was applied in Matlab [Version 8.3
(R2014a), the Mathworks Inc., Natick, MA, USA] to create a sub-network
of metabolic reactions associated with CAC and IMT. The algorithm iden-
tifies the main reaction pairs as defined in the Kyoto Encyclopaedia of
Genes and Genomes (KEGG)36 occurring spontaneously or by the activ-
ity of an enzyme related to Homo sapiens genes and calculates the adja-
cency matrix for all compounds based on these main reaction pairs. The
shortest metabolic paths between all metabolites significantly associated
with IMT and CAC were then determined based on the adjacency matrix
and a network graph was drawn to display the selected metabolites and
all connected compounds with the shortest paths.
Ingenuity pathway analysis
We used Ingenuity Pathway Analysis (IPA) to investigate the gene and
metabolite networks linked to the 1H NMR-derived metabolites of ath-
erosclerosis.37 First, we uploaded the list of CAC-IMT associated metab-
olites into IPA, considering only experimentally observed molecular
relationships with the maximum number of molecules per generated mo-
lecular network included as the default. IPA generated a shortlist of inter-
action networks around the metabolites of interest. These were then
merged into a single combined network.
Results
Table 1 shows the baseline characteristics across the three studies
and Supplementary material online, Figure S6 shows the flowchart of
participants in this study.
Nuclear magnetic resonance
metabolomics and atherosclerosis
We analysed the full resolution metabolic profiles27 from standard
1D NMR and CPMG NMR spectra in relation to CAC and IMT.16
For 1D NMR, 7935 spectral features, corresponding to 74 NMR
spectral regions (clusters, see Methods section) were associated with
CAC in MESA (P< 1.8  10-5) and of them 41 regions were repli-
cated (P< 0.05) in samples from Rotterdam Study and LOLIPOP
(Figure 1A, Supplementary material online, Table S2). From these fea-
tures, 19 metabolites were annotated (Supplementary material on-
line, Table S2); we were unable to annotate two regions which
corresponded to broad signals present in the spectral baseline, likely
corresponding to multiple overlapping resonances from serum pro-
teins (see Methods and Supplementary material online, Figures S2–
S5). Overall 10 metabolites were directly associated with CAC (ala-
nine, glycine, methionine, glucose, acetaminophen-glucuronide,
glycerol, acetyl glycoproteins, myo-inositol, mannose, and 1,5-anhy-
drosorbitol) and 9 were inversely associated (glutamate, glutamine,
N,N-dimethylglycine, lysine, phenylalanine, 5-oxoproline, 3-hydroxy-
butyrate, citrate, and albumin).
In discovery analyses, where IMT was used instead of CAC as the
marker of atherosclerosis, 22 annotated metabolites were replicated
in the analysis of the pooled Rotterdam Study and LOLIPOP samples
including 1-methylhistidine, 3-hydroxybutyrate, aspartate, and tyro-
sine (inverse), and lactate, and valine (direct) (Figure 1B,
Supplementary material online, Table S3). Of these 22 metabolites,
12 were replicated metabolites associated with CAC, while 10 were
only associated with IMT but not CAC.
In analyses of CPMG NMR data, we identified five additional
metabolites associated with CAC and IMT (Supplementary material
online, Tables S2 and S3).
Adjustment for cardiovascular disease
risk factors
After further adjustment for CVD risk factors, the magnitude of the
aforementioned association between the metabolites and athero-
sclerosis attenuated by at least 50%. In detail, mannose, alanine, and
acetaminophen-glucuronide showed strong direct associations and
glutamate and histidine strong inverse associations with CAC below
the MWAS significance threshold (P= 2.4  10-9 to 1.1  10-5); all
other replicated metabolites remained nominal statistically significant
2886 I. Tzoulaki et al.
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histidine, N,N-dimethylglycine, and albumin showed strong inverse
associations below the MWSL threshold (P= 7 10-7 to 6.7 10-6);
14 other metabolites retained nominal statistical significance
(P< 0.05). Only histidine was associated with both CAC and IMT at
MWSL significance level after adjustment for CVD risk factors. In
stepwise linear regression with CVD risk factors, acetaminophen glu-
curonide and histidine remained in the model for CAC and histidine
and albumin for IMT (Supplementary material online, Figure S7). In
sensitivity analyses, exclusion of people receiving treatment for blood
pressure, diabetes or lipids, and analyses adjusting for BMI in addition
to CVD risk factors did not materially affect these results
(Supplementary material online, Tables S4–S8).
Metabolites associated with incident
cardiovascular disease
Figure 2A shows the 1D NMR metabolites that were replicated in
their associations with either CAC or IMT. There was considerable
overlap and consistency in the metabolic signature between the two
phenotypes with all metabolites showing the same direction of asso-
ciation between the atherosclerotic measures. The majority of
metabolites that were associated with measures of atherosclerosis
were also associated with incident CVD events available in MESA and
Rotterdam Study participants (Figure 2B, Supplementary material
online, Table S9) with 25 out of 30 metabolites reaching nominal stat-
istical significance (P< 0.05). However, adjustment for CVD risk fac-
tors attenuated all associations markedly with only acetaminophen
glucuronide showing a P-value smaller than 0.05.
Lipoproteins associated with
atherosclerosis and incident
cardiovascular disease
To reveal more detailed information on lipoprotein content, we
used the Bruker Lipoprotein Subclass Analysis to deconvolve two
specific 1D NMR signals corresponding to the lipid moiety CH3-
CH2-R in MESA data (see Methods section). Overall, 35/105 lipo-
protein subclasses were significantly (P< 0.005) associated with
CAC and three of them (total plasma cholesterol, total plasma
apolipoprotein B, and apolipoprotein B within total plasma LDL)
retained statistical significance (P< 0.005) after adjustment for
non-lipid CVD risk factors (Figure 3, Supplementary material on-
line, Table S10). For IMT, associations with lipids were stronger
and 74/105 and 63/105 lipoproteins showed significant (P< 0.005)
associations in minimal and fully adjusted models, respectively
(Figure 3, Supplementary material online, Table S11). The pattern
of the association between lipoproteins and IMT and CAC was
again consistent between the two measurements (Figure 3,
Supplementary material online, Tables S11 and S12). Lipoproteins
....................................................................................................................................................................................................................
Table 1 Numbers of individuals, and means (standard deviation) or percent for demographic, anthropometric and
clinical outcome variables
LOLIPOP Rotterdam MESA All
N 1917 1652 3867 7436
Gender (female/male) 662/1255 887/765 1957/1910 3506/3930
Age (years) 54.8 (10) 70.8 (5.7) 62.9 (10.3) 62.6 (10.9)
Body mass index (kg/m2) 27.4 (4.4) 27 (3.9) 28.1 (5.4) 27.7 (4.9)
Coronary artery calcium (CAC) >0 (%) 1011 (52.7) 1491 (90.3) 2016 (52.1) 4518 (60.8)
CAC (Agatston score) 154.1 (439.6) 486.6 (915.6) 155.3 (423.6) 228.6 (590.2)
Coronary artery calcium (log(CAC þ 1)) 2.2 (2.5) 4.4 (2.4) 2.3 (2.6) 2.8 (2.7)
Intima-media thickness (IMT) (mm) 0.7 (0.1) 1.1 (0.2) 0.8 (0.2) 0.8 (0.2)
Intima-media thickness (log10(IMT)) -0.2 (0.1) 0 (0.1) -0.1 (0.1) -0.1 (0.1)
Systolic blood pressure (mmHg) 131.3 (18.9) 143.1 (21.2) 127 (21.4) 131.7 (21.7)
Total cholesterol (mg/dL) 209.9 (40.4) 224.5 (37) 194 (35) 204.9 (38.9)
HDL cholesterol (mg/dL) 52.3 (13.5) 53.8 (14.9) 50.9 (14.7) 51.9 (14.5)
LDL cholesterol (mg/dL) 130.9 (34.6) 144.2 (33.6) 117.3 (31.4) 126.8 (34.5)
Diabetes (%) 287/1630 (15) 236/1416 (14.3) 537/3330 (13.9) 1060/6376 (14.3)
Current smoker (%) 205/1712 (10.7) 284/1368 (17.2) 467/3400 (12.1) 956/6480 (12.9)
Ethnicity (%) 813 (42.4%) Caucasian 1652 (100%) Caucasian 1492 (38.6%) Caucasian 3952 (53.2%) Caucasian
1104 (57.6%) Indian 521 (13.5%) Asian 1104 (14.8%) Indian
949 (24.5%) African 521 (7%) Asian
905 (23.4%) Spanish 949 (12.8%) African
905 (12.2%) Spanish
Lipid lowering treatment (yes/no) (%) 303/1614 (15.8) 252/1400 (15.3) 641/3226 (16.6) 1196/6240 (16.1)
Blood pressure treatment (yes/no) (%) 494/1423 (25.8) 646/1006 (39.1) 1463/2404 (37.8) 2603/4833 (35)
Diabetes treatment (yes/no) (%) 287/1630 (17.6) 97/1555 (6.2) 381/3486 (10.9) 765/6671 (11.5)
Incident cardiovascular events (yes/no) (%) — 379/1093 (16) 251/3613 (6.5) 487/4849 (9.1)
Metabolic signatures of atherosclerosis 2887
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/40/34/2883/5490734 by Erasm
us U
niversity R
otterdam
 user on 30 O
ctober 2019
Figure 1 Manhattan-type plot showing the analysis of the 30 590 Carr-Purcell-Meiboom-Gill nuclear magnetic resonance (upper panel) and one-
dimensional nuclear magnetic resonance (lower panel) features with (A) coronary artery calcium and (B) intima-media thickness in minimal adjusted
model (Model 1: age, sex, cohort, and ethnicity) and fully adjusted model (Model 2: low and high-density lipoproteins, lipid and blood pressure lower-
ing treatment, systolic blood pressure, smoking status, and diabetes). The signed -log10 P-value (on the y-axis) is derived from Model 1. The black
dots represent the data points remaining significant after multiple testing correction (1.8 10-5 for one-dimensional nuclear magnetic resonance and
(continued)
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..were also associated with incident CVD with apolipoprotein B
and free cholesterol in very low-density lipoproteins showing the
strongest associations and overall lower density lipoproteins
showing stronger direct associations with atherosclerosis and
CVD events (Figure 3, Supplementary material online, Table S12).
Triglycerides in all measured major lipoprotein subclasses includ-
ing HDL were positively associated with higher risks of CVD.
Metabolic pathways
Correlations between the metabolites revealed a strong dependence
structure between the replicated metabolic signals (Figure 4A).
Metabolite markers of atherosclerosis and CVD risk factors, including
blood pressure and lipids, were strongly associated in the same direc-
tion as the associations with CAC and IMT (Figure 4B). The human
metabolic network from KEGG was used to compute the shortest
metabolic paths between metabolite markers of atherosclerosis, and
plot their connectivities in a network graph (a so-called ‘metab-
onetwork’,25 Figure 5). The figure illustrates disturbances of pathways
including those related to lipid, fatty acid and carbohydrate metabol-
ism, branched chain amino acid (BCAA) and aromatic acid metabol-
ism, tricarboxylic acid (TCA), and urea cycle and muscle metabolism.
We further investigated gene and metabolite networks by integrating
our results with previously experimentally observed molecular rela-
tionships using Ingenuity Pathway Analysis (IPA, Supplementary ma-
terial online, Figure S8). IPA revealed an interaction network between
genes mainly involved in inflammatory, insulin and lipid pathways, and
our 1H NMR-identified metabolite markers of atherosclerosis.
Discussion
In this study of over 7000 participants from three prospective
population-based cohorts, we present the metabolic signature of ath-
erosclerosis offering insights into the widespread systemic disturban-
ces underlying atherosclerosis. Atherosclerosis was associated with
disturbances of inter-connected pathways related to lipid, fatty acid
and carbohydrate metabolism, BCAA and aromatic acid metabolism,
TCA and urea cycle, and muscle metabolism and showed a largely
consistent pattern between coronary and carotid atherosclerosis.
Subsequently, these metabolites were also associated with incident
CVD events highlighting the importance of these pathways in pro-
gression to clinical CVD. The fact that the majority of these associa-
tions attenuated substantially after adjustment for conventional CVD
risk factors suggests that these metabolites lie on pathways closely
associated with CVD risk factors.
Beyond KEGG pathways, replicated metabolites highlight oxidative
stress and inflammatory pathways. For example, 5-oxoproline and
glutamate, both inversely associated with CAC and IMT, are involved
in both synthesis and degradation of glutathione. Glutathione defi-
ciency contributes to oxidative stress, which plays a key role in the
pathogenesis of atherosclerosis.38,39 N-acetylneuraminic acid, posi-
tively associated with CAC and IMT, is the major form of sialic acid in
mammals and serves as a biomarker of a sustained inflammatory re-
sponse with subsequent effects on atherosclerosis.39,40 Glycoprotein
acetyls have previously shown associations with risk of MI and
stroke,41 and here, we also report consistent effects with CAC and
IMT. In addition, lactate, also associated positively with IMT, formed
from pyruvate under insufficient oxygen supply (hypoxia), is an indi-
cator of inflammation. Local hypoxia can occur in highly active
inflamed tissues where demands from increased cellularity exceed
oxygen supply, a feature of atherosclerotic plaque.42 Hypoxia has
been hypothesized to stimulate pro-atherosclerotic processes,
including deficient lipid efflux, inflammation, interference with macro-
phage polarization and glucose metabolism.43
The four metabolites linked to sugar and carbohydrate metabolism
(D-glucose, 1,5-anhydrosorbitol, D-mannose, and myo-inositol)
were all directly associated with both CAC and/or IMT after adjust-
ment for CVD risk factors. 1,5-anhydrosorbitol, a marker of glycaem-
ic control, has previously been associated with CVD and kidney
disease and highlights the close association of atherosclerotic disease,
diabetes and insulin resistance.38,44,45 Mannose has repeatedly been
associated with pre-diabetes, incident Type 2 diabetes,46 and all-
cause mortality,47 and here, we highlight associations with athero-
sclerosis and incident CVD, independent of glucose. In this regard,
mannose showed stronger correlations with lipids and N-acetylgly-
coproteins than with glucose (Figure 4). Mannose has a central role in
glycation processes of lipoproteins that in turn may play a role in the
initiation and development of atherogenesis. N-glycans are up-regu-
lated in pro-inflammatory settings and have been found on the endo-
thelial cell surface in early stages of atherosclerotic plaque
development.48 Taken together these data suggest that mannose
could also affect CVD risk through non-glucose dependent
pathways.
Energy metabolism, TCA cycle and glycolysis, were also central
pathways associated with atherosclerosis. Alanine is synthesized dir-
ectly from pyruvate, a product of glycolysis, which can supply the cells
3.7 10-6 for Carr-Purcell-Meiboom-Gill nuclear magnetic resonance, respectively), the blue dots are Model 1 significant in MESA and replicated in
the Rotterdam Study and LOLIPOP (with a P-value <0.05), and the red dots are Model 2 significant. The horizontal axis is the nuclear magnetic reson-
ance chemical shift (in ppm). Median spectra intensity is given in the pooled dataset non-missing for coronary artery calcium/intima-media thickness
together with chemical compounds. Nuclear magnetic resonance assignments: 1, lipids (low-density lipoprotein and very low-density lipoprotein,
CH3-CH2-R, CH3-CH2-C=); 2, isoleucine; 3, leucine; 4, valine; 5, lipids (low-density lipoprotein and very low-density lipoprotein, CH3-CH2-R,
(CH2)n); 6, lactate; 7, alanine; 8, lipids (low-density lipoprotein and very low-density lipoprotein,CH2-CH2-C=, CH2-CH2-CO); 9, arginine; 10, ly-
sine; 11, acetate; 12, lipids (CH2-CH2-CH=CH); 13, N-acetylglycoproteins; 14, methionine; 15, glutamine; 16, lipids (CH2-CO); 17, 3-hydroxybuty-
rate; 18, glutamate; 19, pyruvate; 20, 5-oxoproline; 21, citrate; 22, lipids (CH=CH-CH2-CH=CH); 23, aspartate; 24, albumin; 25, N,N-
dimethylglycine; 26, creatine; 27, creatinine; 28, phenylalanine; 29, histidine; 30, tyrosine; 31, choline; 32, beta-glucose; 33, beta-glucose; 34, glycine;
35, glycerol; 36, myo-inositol; 37, mannose; 38, 1,5-anhydrosorbitol; 39, glyceryl groups of lipids; 40, acetaminophenþ glucuronide; 41, lipids
(CH5CH); 42, uridine; 43, 1-methyl histidine; 44, 3-methylhistidine; and 45, formate.
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Figure 2 (A) Regression coefficients per standard deviation (95% confidence interval) between one-dimensional nuclear magnetic resonance
metabolites associated with coronary artery calcium and/or intima-media thickness using the sentinel (most significant) ppm within each nuclear mag-
netic resonance region (cluster) pooled across all three cohorts (N= 7436) and coronary artery calcium and intima-media thickness. The solid lines
represent Model 1 (adjusted for age, sex, cohort, and ethnicity) and the dotted lines Model 2 (further adjusted for low-density lipoprotein and high-
density lipoprotein, lipid and blood pressure lowering treatment, systolic blood pressure, smoking status, and diabetes). The significance threshold is
given for Models 1 and 2 where *P<_ 0.05, **P<_ 0.01, and ***P<_ 1.8e-05 (metabolome wide significance level for one-dimensional nuclear magnetic
resonance data, see Supplementary material online, Table S1). (B) Hazard ratios (95% confidence interval) per standard deviation between the one-di-
mensional nuclear magnetic resonance metabolites associated with coronary artery calcium and/or intima-media thickness and incident cardiovascu-
lar disease events in MESA and Rotterdam studies (N= 630 events). The significance threshold is given for Models 1 and 2 where *P<_ 0.05,
**P<_ 0.01, and *** P<_ 0.001.
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Figure 2 Continued
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Figure 3 Associations between lipoprotein particles from Bruker analysis in MESA (N= 3753). The solid lines represent Model 1 and the dashed
lined Model 3. (A) The regression coefficient (95% confidence interval) per standard deviation of each lipoprotein between coronary artery calcium
and each nuclear magnetic resonance lipoprotein feature was adjusted for age, sex, ethnicity, and analysis phase (Model 1) and further adjusted for
basic cardiovascular risk factors (diabetes, systolic blood pressure, smoking and medication for hypercholesterolaemia, diabetes or high blood pres-
sure) (Model 3). (B) Hazard ratios (95% confidence interval) for incident cardiovascular disease events (N= 242) and lipoproteins are shown. A sig-
nificance threshold with adjusted Bonferroni correction is given for Models 1 and 2 where *Padj <_0.005, **Padj <_0.001, and ***Padj<_ 0.0001. The
P-value Bonferroni corrected by the number of PCs (10) that account for more than 95% of the total variation in the data set. A P< 0.05/10 (<0.005)
was therefore used to denote statistical significance in these analyses (see Methods section). Analysis of 105 lipoprotein subclasses was carried out
including different chemical components of intermediate-density lipoprotein (density 1.006–1.019 kg/L), very low-density lipoprotein (0.950–1.006
kg/L), low-density lipoprotein (density 1.09–1.63 kg/L), and high-density lipoprotein (density 1.063–1.210 kg/L). The low-density lipoprotein sub-frac-
tion was fractionated into six density classes (low-density lipoprotein-1 1.019–1.031 kg/L, low-density lipoprotein-2 1.031–1.034 kg/L, low-density
lipoprotein-3 1.034–1.037 kg/L, low-density lipoprotein-4 1.037–1.040 kg/L, low-density lipoprotein-5 1.040–1.044 kg/L, low-density lipoprotein-6
1.044–1.063 kg/L), and the high-density lipoprotein sub-fraction in four density classes (high-density lipoprotein-1 1.063–1.100 kg/L, high-density lipo-
protein-2 1.100–1.125 kg/L, high-density lipoprotein-3 1.125–1.175 kg/L, and high-density lipoprotein-4 1.175–1.210 kg/L).
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..with energy through the TCA cycle in aerobic conditions. Increased
glucose utilization has been shown in high-risk atherosclerotic pla-
ques.49 In turn, citrate is an intermediate and key energy metabolite
in the TCA cycle and has previously been associated with cardiovas-
cular mortality.50 Reduced oxygen levels in presence of atheroscler-
osis may affect the TCA cycle since it is oxygen dependent. Creatine,
an amino acid derivative, reflects changes of energy metabolism in
the muscles; it is transported through the circulation and taken up by
tissues with high energy demands, with creatinine as a degradation
product. Their levels have been inversely associated with fat intake in
animal studies.51,52
The lipoprotein profiles analyses confirmed previous observations
investigating the associations of these lipids with subclinical athero-
sclerosis,53 MI, and stroke.41 Here, we further show a largely consist-
ent picture between coronary and carotid atherosclerosis and with
cardiovascular events. Association of triglycerides with atheroscler-
otic disease and future events was positive even within HDL particles
in support of previous observations. Conversely, not all HDL choles-
terol was inversely associated with atherosclerosis highlighting the
fact that causal association of HDL with lower CVD risk may be lim-
ited to certain particles (i.e. not the ones containing triglycerides). In
contrast, LDL and VLDL was consistently positively associated with
higher CAC and IMT and higher risk of CVD events with a small
trend showing stronger associations with decreasing density of
lipoproteins.
The molecular interaction gene network map (Supplementary ma-
terial online, Figure S6) further depicts the interconnections between
inflammatory, insulin, and lipid pathways reflected by metabolite
markers of atherosclerosis. For example, the network includes fibro-
nectin 1 (FN1), which is involved in cell adhesion and migration proc-
esses including wound healing, blood coagulation, and host defence;
genetic polymorphisms within this gene have been associated with
adverse lipid levels and coronary heart disease.54,55 Other examples
include CCAAT/enhancer-binding protein beta, a master regulator of
immunity and inflammation, other immunity related genes (e.g. PI3K
complex), and pathways related to betaine-homocysteine metabol-
ism (BHMT), glycolysis (pyruvate kinase), and angiogenesis (ANGPT4).
Our study has several strengths. To our knowledge, it is the largest
to investigate the metabolic signature of atherosclerosis using both
standard 1D and CPMG 1H NMR spectra with information on small
molecules and lipoprotein subclasses. We replicated our findings in
external independent populations and we used two phenotypes of
atherosclerosis (CAC and IMT) to further increase the generalizabil-
ity and robustness of our findings. We characterized the underlying
biological pathways associated with the metabolites of interest, high-
lighting extensive inter-connected disturbances of metabolism.
BA
Figure 4 (A) Partial correlations between markers of coronary artery calcium or intima-media thickness in MESA (N= 3948), using sentinel ppm
for each one-dimensional or Carr-Purcell-Meiboom-Gill assigned metabolite (N= 35). †Metabolite assessed in Carr-Purcell-Meiboom-Gill data.
Adjusted analysis controlling for sex, age, ethnicity, and measurement phase. ***The threshold after Bonferroni correction for 560 tests ensuring a
Family-Wise Error Rate control at 0.1% (0.001/560), ** at 1% (0.01/560), and * at 5% (0.05/560). (B) Spearman correlation matrix between metabo-
lites associated with coronary artery calcium and/or intima-media thickness (N= 35) and cardiovascular disease risk factors, using the sentinel (most
significant) ppm within each nuclear magnetic resonance region (cluster) in MESA (N= 3948) with colour-keyed correlation coefficient. Hierarchical
clustering was used to reorder the correlation matrix. The size of the squares is proportional to the significance level; statistical significance was set
to a Bonferroni threshold correction ensuring a Family-Wise Error Rate control at 5%. †Metabolite detected in the Carr-Purcell-Meiboom-Gill data.
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..One limitation of our study is the cross-sectional nature of associa-
tions of metabolites with sub-clinical atherosclerosis; however, we
also examined our results in relation to prospective data using inci-
dent CVD events. Nonetheless, as with any observational study, caus-
ality cannot be inferred and further experimental and functional work
is needed to further elucidate the metabolic pathways involved in ath-
erosclerotic disease. We studied metabolites present in blood which
may not accurately reflect metabolic processes in atherosclerotic pla-
ques and arterial tissue, although there is strong evidence to suggest
that at least some blood biomarkers (e.g. cholesterol) are relevant to
atherosclerosis and blood is a readily accessible tissue for identifica-
tion of prognostic or diagnostic markers. Finally, since we used a
untargeted metabolic profiling approach, some of the discovered
metabolic features could not be annotated (as expected); however,
most of the unannotated signatures correspond to broad signals
most likely from protein residues which cannot be further annotated
by NMR. At the same time, this untargeted (‘agnostic’) approach
allows for the discovery of metabolites that are not part of targeted
panels. Our analysis was limited to NMR and mass spectrometry data
may offer additional insights not apparent based on NMR data alone.
In summary, in this study of over 7000 participants from three
prospective population-based cohorts, we found strong associa-
tions between serum metabolites observed on 1H NMR spec-
troscopy and subclinical atherosclerosis which was largely
consistent between the two vascular beds (coronary and carotid
arteries). Our metabolic and gene networks reveal highly inter-
connected system level metabolic disturbances in atheroscler-
osis, much of which overlaps with the known cardiovascular risk
Figure 5 Multicompartmental metabolic network characterizing subclinical atherosclerosis. Metabolites highlighted in strong colours passed the
multiple testing correction in MESA (1.8 10-5) and were replicated in independent populations (the Rotterdam Study and LOLIPOP) for Model 1
(adjusted for age, sex, cohort, and ethnicity) in relation to coronary artery calcium and/or intima-media thickness. Nodes and edges in the graph rep-
resent metabolites and reactions from the Kyoto Encyclopaedia of Genes and Genomes. Metabolites from Kyoto Encyclopaedia of Genes and
Genomes are included in the ‘metabonetwork’25 if they were present on the set of shortest paths between the metabolites associated with coronary
artery calcium/intima-media thickness. The direction of association between metabolites and coronary artery calcium/intima-media thickness is illus-
trated in the graph by the orange (direct) and blue (inverse) colours, and was consistent within each pathway. Full names of abbreviations are listed in
the Supplementary material online, Table S14.
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..factors. Genetic approaches as well as mechanistic studies are
now needed to further validate our results and to follow-up the
possible entry points for investigation of novel targets or pre-
ventive strategies for atherosclerotic disease.
Supplementary material
Supplementary material is available at European Heart Journal online.
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